Rheumatoid arthritis (RA)-associated interstitial lung disease (RA-ILD) is an increasingly common extra-articular cause of mortality and morbidity in RA. Here, we present the case of an 82-year-old female suffering from RA-ILD. She presented with a 20-year history of RA with new-onset progressively worsening dyspnoea, pyrexia, and dry cough, which were not responsive to initial antibiotics. Moreover, she had been on long-term methotrexate, which can cause pulmonary disease. Investigations revealed raised inflammatory markers, restrictive lung patterns, and radiological features of ILD. She was treated with a tapering course of oral prednisolone and home oxygen, which provided some symptomatic improvement. Diagnosis of RA-ILD can be challenging due to several contributing factors. Optimal treatment is controversial, and corticosteroids have been widely used but with limited effects. There is evidence directed at potential therapeutic benefit from a number of newer agents, which are discussed.
Introduction
It is estimated that nearly half of patients with rheumatoid arthritis (RA) will develop some form of associated respiratory complication in their lifetime. 1 Of these, interstitial lung disease (ILD), characterized by inflammation, scarring, and fibrosis of lung tissue, is the only complication of RA with an increasing prevalence, accounting for about 7% of deaths in early RA. [2] [3] Moreover, the medications used in treating RA can cause respiratory toxicity and this can complicate diagnosis. Despite several recent promising developments, the understanding of RA-ILD is not well established and its management has not been clearly defined. In light of this, we report a case of RA-ILD that presents a clinical dilemma.
Case Summary
An 82-year-old female presented with a 2-week history of new-onset progressively worsening dyspnoea (both on physical exertion and at rest), pyrexia (37.8°C), and dry cough.
She was initially treated for community- Laboratory workup revealed the following:
In addition, her pulmonary function tests 
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Methotrexate-induced ILD
Methotrexate, the first-line disease-modifying antirheumatic drug (DMARD) in treating RA, is known to cause methotrexate-induced pulmonary toxicity, of which methotrexate pneumonitis (inflammation of lung tissue) is common, 14 and this can progress to pulmonary fibrosis. 15 The most significant risk factor for developing pneumonitis is preexisting pulmonary disease, coupled with a baseline diffusing capacity of < 70%
predicted, which increases the risk of developing methotrexate drug toxicity 10-fold. 16 Other risk factors are listed in 
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Cyclophosphamide has been found to be therapeutic in methotrexate-induced pneumonitis that has not been responsive to the usual methotrexate discontinuation, oxygen therapy, and/or corticosteroids. Other ancillary treatments include annual 
Learning Points
What is known already known  ILD is strongly associated with Rheumatoid Arthritis and its anti-rheumatic medications, such as methotrexate.
 ILD is usually treated with a tapering course of corticosteroids and/or immunosuppressants and managed holistically with ancillary treatments.
What this study adds
 The inclusion of a number of new agents (e.g. mycophenolate mofetil, rituximab, and cyclophosphamide) has provided a better outlook in treating ILD. Thorough consideration must be given to each individual patient's extent of disease, rate of progression and co-morbidities when deciding which treatments to administer.
 Prompt treatment delays disease progression of RA-ILD of arthritis and management revolves around symptom control.
 Multidisciplinary holistic care ensures best practice.
